Codiak BioSciences, Inc

QurAlis Corporation, based in Cambridge, MA, is a pioneering neurology company dedicated to finding effective precision medicines for neurodegenerative diseases such as ALS and FTD. With a relentless pursuit of knowledge and a precise attention to craft, QurAlis aims to alter the trajectory of these diseases by developing therapies that target specific components of ALS pathology and defined patient populations. Driven by the belief that a cure or treatment should exist for every disease and every person, QurAlis has cracked the code on sporadic ALS through the identification of major disease drivers linked to TDP-43 pathology. Through their proprietary investigative platforms, QR43 and FlexASO, QurAlis is breaking through scientific barriers to discover and develop precision therapies for TDP-43-related diseases and tackle the spectrum of diseases that define ALS and other neurodegenerative conditions.Generated from the website

C4 Therapeutics, Inc. is a biotechnology company based in Watertown, MA, specializing in targeted protein degradation. Their innovative approach, known as Targeted Protein Degradation (TPD), aims to develop a new generation of medicines for treating various diseases. Through their TORPEDO platform and focus on target selection, C4 Therapeutics is dedicated to transforming lives by degrading disease-causing proteins. With a strong leadership team, board of directors, and scientific advisory board, C4 Therapeutics is committed to advancing their pipeline of therapies, including CFT7455, CFT1946, and CFT8919. They also collaborate with industry partners such as Roche, Biogen, Betta Merck, and others to further their research and development efforts. At C4 Therapeutics, their values, people, and dedication to scientific progress drive their mission to revolutionize the treatment of diseases through targeted protein degradation.Generated from the website

HiFiBiO Therapeutics is a clinical-stage global biotech company based in Cambridge, MA. They are dedicated to revolutionizing the development of immunotherapies by utilizing their unique high-resolution translational platform, DIS, which provides an unprecedented understanding of immune dysregulation at the single cell level. Their goal is to enhance the probability of success for immunotherapies and improve patient outcomes through single-cell precision. With a focus on single cell science, HiFiBiO Therapeutics applies this approach at every stage of drug development, from target discovery to predictive biomarkers. This enables them to rapidly advance new therapeutics into the clinic, ultimately aiming to unlock the curative powers of the immune system. Through strategic collaborations and groundbreaking initiatives, they are at the forefront of personalized immunotherapies and have been recognized for their innovative Drug Intelligence Science (DIS) platform.Generated from the website